NutraLife Biosciences Launches a Clinically Tested Focus Stimulant Under a Master Distribution Agreement

Rhea-AI Summary

NutraLife Biosciences, Inc. (OTC: NLBS) has announced a master distribution agreement with Whole Foods Full Spectrum Processing for their product, Addy, a focus stimulant designed to enhance attention and mental clarity. Addy is a non-addictive dietary supplement shown to improve working memory and sustained attention, with a clinical study validating its effects. With ADHD prevalence rising globally, the ADHD therapeutics market is expected to grow from $29.56 billion to $45.68 billion by 2027. NutraLife aims to distribute Addy through various retail and online channels, emphasizing its natural formulation.

Positive

• Executed a distribution agreement with Whole Foods Full Spectrum Processing for Addy.
• Addy shown to improve working memory and sustained attention in clinical studies.
• Growing ADHD therapeutics market projected to increase from $29.56 billion to $45.68 billion by 2027.

Negative

• None.

COCONUT CREEK, FL, Oct. 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – NutraLife Biosciences, Inc. (OTC: NLBS), a manufacturer and distributor of private label and branded nutraceutical and skincare products, today announced it has executed a master distribution agreement with Whole Foods Full Spectrum Processing. (“WFFSP”) for the co-marketing and distribution of Addy, a focus stimulant product designed to enhance sustained attention and support better mental clarity.

Developed by WFFSP, Addy is an all-natural, non-addictive dietary supplement shown in a clinical study to improve two of the so-called “executive functions” of the brain: working memory and sustained attention, both of which are considered important to learning, studying, and test performance in academic settings.

According to medical researchers, the prevalence of ADHD and ADD is on the rise in both adults and children here in the U.S. and around the world. With an estimated 9.4% of children and 2.8% of adults coping with hyperactivity disorders, the global ADHD therapeutics market has an estimated value of $29.56 billion this year and is projected to reach $45.68 billion by 2027.

“We are delighted to have this opportunity to distribute this drug-free, non-GMO, and vegetarian supplement available to everyone interested in enhancing their ability to stay on task with greater focus and concentration, but without jitters or other unwanted side effects,” stated Edgar Ward, President, and CEO of NutraLife.

Based in Coconut Creek, Florida, and publicly traded as over-the-counter security for 8-years, NutraLife Biosciences is a developer, manufacturer, and distributor of more than 50 products and formulations designed to support and cater to a multitude of health and wellness applications to help support healthful body function and improve the quality of life.

Formulated by board-certified addiction specialist Dr. Samuel Amen, Addy’s active ingredient is whole green coffee beans which are sustainably sourced and manufactured in an FDA-certified facility. Due to the unique delivery mechanism native to powdered green coffee beans, in a clinical study conducted by the Cleveland Clinic, Addy appeared to support the ability of subjects to stay on task, focus, and more effectively maintain concentration.

“The availability of a natural substance that assists executive function is a highly useful accommodation that can assist in a wide variety of daily tasks, business activities, and academic pursuits,” commented Dr. Samuel Amen, PhD.

The Cleveland Clinic study investigated the effects of WGCP™ on the ability of neurotypical individuals without diagnosed ADHD to exercise executive functions associated with: sustained attention, spatial working memory, response inhibition, and impulsivity, all of which are thought to enhance remote cognitive activity similar to academic study.

Unlike extracted stimulants that can trigger a wide range of adverse side effects, Addy has been clinically shown to increase focus and concentration for 5 to 6 hours in test subjects with no reported side effects.*

To measure the effects of WGCP™ on core executive functions used in standard academic study, the Cleveland Clinic also used the ADHD core battery of the Cambridge neuropsychological test automated battery (CANTAB) and employed a withdrawal protocol to examine the differential effects of WGCP and placebo in neurotypical college-age adults ages 18 to 25 years.

WGCP (“Addy”) is not an ADD/ADHD medication or cure. It is a clinically tested focus & study aid product.

NutraLife Biosciences is making the Addy product available online at www.buyaddy.com/ and will begin distributing the products through various retail, online, and outlets nationwide. 

ABOUT NUTRALIFE BIOSCIENCES, INC.

NutraLife BioSciences, Inc. operates a multifaceted life sciences and lifestyle health and wellness manufacturing company. For more than twelve years, NutraLife has manufactured and distributed both private-label and branded nutraceutical and skincare wellness products.

For more information, visit our website at www.nutralifebiosciences.com.

NutraLife BioSciences, Inc.
6601 Lyons Road, Suite L-6
Coconut Creek, FL 33073
Telephone 888-509-8901
www.NutraLifeBioSciences.com

Forward-Looking Statements

This press release contains statements of a forward-looking nature about NutraLife Biosciences, Inc. (the “Company”). You can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions.  The Company has based these forward-looking statements primarily on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on the Company’s information on the date hereof. These statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors is set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on April 11, 2022. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

FAQ

What is the distribution agreement announced by NutraLife Biosciences on October 27, 2022?

NutraLife Biosciences announced a master distribution agreement with Whole Foods Full Spectrum Processing for co-marketing and distribution of Addy, a focus stimulant product.

What are the benefits of the Addy product from NutraLife Biosciences?

Addy is a non-addictive dietary supplement that has been clinically shown to improve working memory and sustained attention.

What is the expected growth of the ADHD therapeutics market?

The ADHD therapeutics market is projected to grow from $29.56 billion in 2022 to $45.68 billion by 2027.

How is Addy formulated and what clinical support does it have?

Addy is made with sustainably sourced whole green coffee beans and has clinical study support demonstrating its ability to enhance focus and concentration without side effects.

Where can consumers purchase Addy from NutraLife Biosciences?

Addy will be available online at www.buyaddy.com and through various retail outlets nationwide.